Identification of gene expression and DNA methylation of SERPINA5 and TIMP1 as novel prognostic markers in lower-grade gliomas
Identification of gene expression and DNA methylation of SERPINA5 and TIMP1 as novel prognostic markers in lower-grade gliomas
复制标题
鉴定 SERPINA5 和 TIMP1 的基因表达和 DNA 甲基化作为低级别胶质瘤的新型预后标志物
DOI:
10.7717/peerj.9262
复制
发表时间:
2020-06
期刊:
影响因子:
2.7
通讯作者:
Zhi-Cheng Gong
中科院分区:
文献类型:
--
作者:
Wen-Jing Zeng;Yong-Long Yang;Zhi-Peng Wen;Peng Chen;Xiao-Ping Chen;Zhi-Cheng Gong
Background: Lower-grade gliomas (LGGs) is characteristic with great difference in prognosis. Due to limited prognostic biomarkers, it is urgent to identify more molecular markers to provide a more objective and accurate tumor classification system for LGGs..Methods:In the current study, we performed an integrated analysis of gene expression data and genome-wide methylation data to determine novel prognostic genes and methylation sites in LGGs..Results: To determine genes that differentially expressed between 44 short-term survivors (SERPINA5 and TIMP1 were selected for further study. Kaplan–Meier plots showed that SERPINA5 and TIMP1 expression were significantly correlated with overall survival (OS) and relapse-free survival (RFS) in TCGA LGGs patients. We next validated the correlation between the candidate genes expression and clinical outcome in CGGA LGGs patients. Multivariate analysis showed that TIMP1 mRNA expression had a significant prognostic value independent of other variables (HR = 4.825, 95% CI = 1.370–17.000, P=0.014). Then, differential methylation sites were identified from differentially candidate gene expression groups, and all four methylation sites were significantly negatively correlated with gene expression (spearman rP P SERPINA5 cg15509705 (P = 0.0762)..Conclusion: Taken together, these findings indicated that the gene expression and methylation of SERPINA5 and TIMP1 may serve as prognostic predictors in LGGs and may help to precise the current histology-based tumors classification system and to provide better stratification for future clinical trials.
登录
查看更多内容
DOI:
10.1016/s1040-1741(10)79529-4
发表时间:
2010
期刊:
Yearbook of Oncology
影响因子:
--
作者:
R. Arceci
通讯作者:
R. Arceci
DOI:
10.1111/bpa.12171
发表时间:
2014-09
期刊:
Brain pathology (Zurich, Switzerland)
影响因子:
--
作者:
Louis DN;Perry A;Burger P;Ellison DW;Reifenberger G;von Deimling A;Aldape K;Brat D;Collins VP;Eberhart C;Figarella-Branger D;Fuller GN;Giangaspero F;Giannini C;Hawkins C;Kleihues P;Korshunov A;Kros JM;Beatriz Lopes M;Ng HK;Ohgaki H;Paulus W;Pietsch T;Rosenblum M;Rushing E;Soylemezoglu F;Wiestler O;Wesseling P;International Society Of Neuropathology--Haarlem
通讯作者:
International Society Of Neuropathology--Haarlem
影响因子:
2.7
作者:
Xu, Yang;Geng, Rongxin;Chen, Qianxue
通讯作者:
Chen, Qianxue
影响因子:
64.8
作者:
Lu, Chao;Ward, Patrick S.;Kapoor, Gurpreet S.;Rohle, Dan;Turcan, Sevin;Abdel-Wahab, Omar;Edwards, Christopher R.;Khanin, Raya;Figueroa, Maria E.;Melnick, Ari;Wellen, Kathryn E.;O'Rourke, Donald M.;Berger, Shelley L.;Chan, Timothy A.;Levine, Ross L.;Mellinghoff, Ingo K.;Thompson, Craig B.
通讯作者:
Thompson, Craig B.
影响因子:
4.8
作者:
M. Crocker;B. Bell;S. Zacharoulis;M. Papadopoulos
通讯作者:
M. Crocker;B. Bell;S. Zacharoulis;M. Papadopoulos